At the Annual General Meeting on June 30, 2021, it was decided that the Chairman of the Board will contact the three largest shareholders in terms of votes according to Euroclear’s printout of the share register as of September 30, 2021, each of whom appoints a member of the Nomination Committee. In the event that any of the three largest shareholders does not wish to appoint a member of the Nomination Committee, the fourth largest shareholder shall be consulted and so on until the Nomination Committee consists of three members.
After the Chairman of the Board has had contact with the largest shareholders, the Nomination Committee consists of the following members:
- Hans Derninger proposed by the Vidar Foundation
- Heli Kurjanen
- Mika Kurjanen
Shareholders who have proposed members to the Nomination Committee together represent approximately 22.0% of the total number of shares and votes in the Company. The Nomination Committee appoints a chairman from among its members.
The Nomination Committee’s task is to submit proposals to the 2022 Annual General Meeting regarding the election of the Chairman of the Meeting, number of Board members, Board members, Chairman of the Board and auditors. Determination of fees and other remuneration to the Board and its committees, with a division between the Chairman and other members, as well as remuneration to auditors. The Nomination Committee shall also propose principles for the formation of the Nomination Committee prior to the 2023 Annual General Meeting.
Shareholders who wish to submit proposals and views to the Nomination Committee can do so to PEPTONIC medical AB (publ), Att: Nomination Committee, Gustavslundsvägen 143, 167 51 Bromma, or via e-mail to email@example.com Attention Nomination Committee. In order for the Nomination Committee to be able to process received proposals in a constructive manner, these should be received by the Nomination Committee no later than 1 March 2022.
The Nomination Committee’s proposal will be published in the notice convening the Annual General Meeting 2022 and on the company’s website. The Annual General Meeting of PEPTONIC medical AB (publ) is planned to be held on May 24, 2022.
For more information, please contact:
Hans von Celsing,
Chairman of the Board,
PEPTONIC medical AB (publ),
+46 8 530 20 110
About Peptonic Medical AB
Peptonic Medical AB (publ) is an innovative medtech company that conducts research, development and sales of medical devices and lifestyle products in the field of women’s health. Peptonic launched its first product, VagiVital®️ Active Gel against vaginal atrophy, in July 2018. In April 2021, VagiVital®️ Moisturizing V Cleanser, was launched, a moisturizing and preventive intimate wash. The company was founded in 2009 and the share has been traded on Spotlight (www.spotlightstockmarket.com) in Stockholm since 2014.
Since August 2020, Lune Group Oy Ltd. has been a wholly owned subsidiary of Peptonic Medical. The company was founded in 2005 with the purpose to lead a light-hearted menstrual revolution in positive spirit via patented menstrual cups. The company is now evolving into leading the way in sustainable, intimate well-being.
In October 2021, all assets of Israeli company Common Sense Ltd were acquired. Common Sense has developed unique and patented self-tests to accurately diagnose bacterial vaginosis and amniotic fluid leakage respectively.